Inventor · disambiguated record
Reginald M. Gorczynski
Also filed as: GORCZYNSKI REGINALD · GORCZYNSKI REGINALD M
21 granted patents·8 pending applications·402 citations·filing 2000–2020
96Inventor score
Files withTRILLIUM THERAPEUTICS INC15GORCZYNSKI REGINALD M5D5PHARMA INC2GORCZYNSKI REGINALD2NETWORK IMMUNOLOGY INC2
Top patents by PatentIndex Score
29 records- 0197US7238352B2Methods and compositions for modulating tumor growthTRILLIUM THERAPEUTICS INC·Filed 2005·Granted Jul 3, 2007·43 cites·5 claims
- 0296US7887798B2Methods of treating cancer by administering antibodies to CD200TRILLIUM THERAPEUTICS INC·Filed 2008·Granted Feb 15, 2011·20 cites·12 claims
- 0396US6955811B2Methods of inhibiting immune response suppression by administering antibodies to OX-2TRILLIUM THERAPEUTICS INC·Filed 2001·Granted Oct 18, 2005·51 cites·9 claims
- 0495US7452536B2Methods of treating cancer by administering antibodies to CD200TRILLIUM THERAPEUTICS INC·Filed 2007·Granted Nov 18, 2008·23 cites·19 claims
- 0595US6338851B1Method of suppressing an immune response to a transplanted organ or tissue by administering an OX-2 proteinTRANSPLANTATION TECHNOLOGIES I·Filed 2000·Granted Jan 15, 2002·64 cites·14 claims
- 0694US7902151B2Methods and compositions for modulating immunityTRILLIUM THERAPEUTICS INC·Filed 2009·Granted Mar 8, 2011·19 cites·15 claims
- 0793US6984625B2Methods and compositions for modulating autoimmunityTRILLIUM THERAPEUTICS INC·Filed 2001·Granted Jan 10, 2006·40 cites·14 claims
- 0893US6749854B2Use of OX-2 to inhibit fetal lossTRILLIUM THERAPEUTICS INC·Filed 2001·Granted Jun 15, 2004·41 cites·12 claims
- 0993US6652858B2Use of OX-2 to suppress an immune responseTRILLIUM THERAPEUTICS INC·Filed 2001·Granted Nov 25, 2003·39 cites·13 claims
- 1088US7368535B2CD200 receptorsTRILLIUM THERAPEUTICS INC·Filed 2002·Granted May 6, 2008·39 cites·10 claims
- 1179US7223729B2Methods of treating allergy by administering a CD200 proteinTRILLIUM THERAPEUTICS INC·Filed 2004·Granted May 29, 2007·4 cites·7 claims
- 1278US7205386B2Truncated CD200TRILLIUM THERAPEUTICS INC·Filed 2001·Granted Apr 17, 2007·10 cites·6 claims
- 1373US9938533B2DNA aptamers specific to CD200R1 and their therapeutic usesD5PHARMA INC·Filed 2015·Granted Apr 10, 2018·2 cites·20 claims
- 1468US7291330B2MD-1 inhibitors as immune suppressantsTRILLIUM THERAPEUTICS INC·Filed 2001·Granted Nov 6, 2007·3 cites·3 claims
- 1563US2009214573A1Modulation of bne developmentGORCZYNSKI REGINALD·Filed 2009·Application pending·0 cites
- 1662US7553811B2Methods and compositions for modulating immunityTRILLIUM THERAPEUTICS INC·Filed 2007·Granted Jun 30, 2009·0 cites·2 claims
- 1758US7196243B2Transgenic animal containing CD200 and uses thereforTRILLIUM THERAPEUTICS INC·Filed 2003·Granted Mar 27, 2007·2 cites·9 claims
- 1857US8187598B2Methods of treating cancer by administering antibodies to CD200GORCZYNSKI REGINALD M·Filed 2011·Granted May 29, 2012·0 cites·8 claims
- 1957US2011206668A1Methods and compositions for modulating immunityTRILLIUM THERAPEUTICS INC·Filed 2011·Application pending·0 cites
- 2051US7968103B2Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver componentsWESTPHAL OTTO·Filed 2004·Granted Jun 28, 2011·2 cites·17 claims
- 2151US2011189201A1Modulation of bone developmentGORCZYNSKI REGINALD·Filed 2011·Application pending·0 cites
- 2249US10584342B2DNA aptamers specific to CD2000R1 and their therapeutic usesD5PHARMA INC·Filed 2018·Granted Mar 10, 2020·0 cites·19 claims
- 2349US2005287603A1Modulation of bone developmentGORCZYNSKI REGINALD M·Filed 2003·Application pending·0 cites
- 2449US2008267967A1Modulation of cd200 receptorsGORCZYNSKI REGINALD M·Filed 2008·Application pending·0 cites
- 2546US8206897B2Assay for soluble CD200GORCZYNSKI REGINALD M·Filed 2008·Granted Jun 26, 2012·0 cites·9 claims
- 2645US2016184404A1Novel hemoglobin-derived peptide based pharmaceutical compositionsCLINIQUE LA PRAIRIE·Filed 2014·Application pending·0 cites
- 2741US12090202B2Combination of plasma immunoglobulin and antigen-specific immunoglobulin for the modification of the immune system and the treatment or prevention of allergic diseasesNETWORK IMMUNOLOGY INC·Filed 2019·Granted Sep 17, 2024·0 cites·18 claims
- 2841US2022356232A1A combination of plasma immunoglobulin and antigen-specific immunoglobulin for the modification of the immune system and the treatment or prevention of autoimmune diseasesNETWORK IMMUNOLOGY INC·Filed 2020·Application pending·0 cites
- 2935US2012264145A1Assay for Soluble CD200GORCZYNSKI REGINALD M·Filed 2012·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →